Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.70 |
| ▸ | CHUK | O15111 | 5/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3799484 | 0.94 | IKBKB (0.71) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL552629 | 0.93 | IKBKB (0.70) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL14366024 | 0.91 | IKBKB (0.74) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL552176 | 0.90 | IKBKB (0.72) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3797643 | 0.89 | IKBKB (0.75) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3792395 | 0.87 | IKBKB (0.78) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3797158 | 0.86 | IKBKB (0.90) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3796790 | 0.85 | IKBKB (0.74) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3800746 | 0.84 | IKBKB (0.86) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3797653 | 0.84 | IKBKB (0.72) | IKBKBCHUKAURKAFLT3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | claimed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254873-A1 | Chemical Compounds | IKBKG, NFKBIA, RELA | IKBKB 5/4885CHUK 9/4885AURKA 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.